v3.26.1
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Mar. 27, 2026
Mar. 02, 2026
Nov. 12, 2025
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
May 11, 2026
Product Liability Contingency [Line Items]                
Royalty percentage   2.00%            
Net sales        
License agreement description           (1) obtain an IND for a patent product within 1 year of the effective date of the agreement, (2) commence a Phase II trial within 2 years of the effective date of the agreement, and (3) submit an NDA or BLA to the FDA or equivalent regulatory agency in another jurisdiction within 7 years of the effective date of the agreement. Pursuant to the Enviro-Cedars License Agreement (Mitochondrial DNA), Enviro was obligated to (1) complete preclinical studies of a patent product within 2 years of the effective date of the agreement, (2) complete toxicology studies within 2.5 years of the effective date of the agreement, (3) obtain IND within 3 years of the effective date of the agreement, (4) begin a Phase I trial within 4 years of the effective date of the agreement, and (5) submit an NDA or BLA to the FDA or equivalent regulatory agency in another jurisdiction within 7 years of the effective date of the agreement. If the Commercialization Milestones are not met or extended, Cedars may convert the exclusive licenses into non-exclusive licenses or to a co-exclusive licenses or terminate the licenses.    
Milestone payments payable   $ 15,000            
Non-US [Member] | Food and Drug Administration [Member]                
Product Liability Contingency [Line Items]                
Payment for milestone           $ 1,500    
Phase I Clinical Trial [Member]                
Product Liability Contingency [Line Items]                
Payment for milestone           150    
Item 1 And 2 [Member] | Phase II [Member]                
Product Liability Contingency [Line Items]                
Payment for milestone           250    
Item 3 [Member] | Phase II Clinical Trial [Member]                
Product Liability Contingency [Line Items]                
Payment for milestone           500    
Item 1, 2 and 3 [Member]                
Product Liability Contingency [Line Items]                
Payment for milestone           250    
Net sales           5,000    
Item 4 [Member]                
Product Liability Contingency [Line Items]                
Payment for milestone           2,500    
Net sales           50,000    
Item 4 [Member] | Food and Drug Administration [Member]                
Product Liability Contingency [Line Items]                
Payment for milestone           1,500    
Item 4 [Member] | Phase II Clinical Trial [Member]                
Product Liability Contingency [Line Items]                
Payment for milestone           250    
Item 4 [Member] | Phase I Clinical Trial [Member]                
Product Liability Contingency [Line Items]                
Payment for milestone           150    
Exclusive License Agreement [Member]                
Product Liability Contingency [Line Items]                
License fee           5    
Annual maintenance fee           $ 10    
Royalty percentage           3.75%    
Exclusive License Agreement [Member] | Item 4 [Member]                
Product Liability Contingency [Line Items]                
License fee           $ 50    
Annual maintenance fee           $ 10    
Royalty percentage           4.25%    
Minimum requirerment of capital       $ 500   $ 500    
Patent product sales           0.50%    
Exclusive License Agreement [Member] | Minimum [Member]                
Product Liability Contingency [Line Items]                
Patent protection costs           $ 9    
Other non-royalty sublicense fees percentage           5.00%    
Exclusive License Agreement [Member] | Minimum [Member] | Item 4 [Member]                
Product Liability Contingency [Line Items]                
Other non-royalty sublicense fees percentage           5.00%    
Exclusive License Agreement [Member] | Maximum [Member]                
Product Liability Contingency [Line Items]                
Patent protection costs           $ 61    
Other non-royalty sublicense fees percentage           35.00%    
Exclusive License Agreement [Member] | Maximum [Member] | Item 4 [Member]                
Product Liability Contingency [Line Items]                
Other non-royalty sublicense fees percentage           35.00%    
Enviro Cedars License Agreements [Member] | Item 1 And 2 [Member] | Phase III [Member]                
Product Liability Contingency [Line Items]                
Net sales           $ 100,000    
Enviro Cedars License Agreements [Member] | Phase III Clinical Trial [Member]                
Product Liability Contingency [Line Items]                
Net sales           50,000    
Lonza Amendment [Member]                
Product Liability Contingency [Line Items]                
Payments for purchase of assets $ 2,000   $ 1,143          
Payments for purchase of assets           $ 193    
Pharmaceutical Development Services Agreement [Member]                
Product Liability Contingency [Line Items]                
Total committed amount               $ 783